Mascoma Wealth Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $129K | Buy |
1,018
+6
| +0.6% | +$791 | 0.02% | 122 |
|
|
2026
Q1 | $141K | Hold |
1,012
| – | – | 0.03% | 114 |
|
|
2025
Q4 | $124K | Buy |
1,012
+15
| +2% | +$1.82K | 0.03% | 117 |
|
|
2025
Q3 | $111K | Hold |
997
| – | – | 0.02% | 130 |
|
|
2025
Q2 | $111K | Hold |
997
| – | – | 0.03% | 121 |
|
|
2025
Q1 | $112K | Hold |
997
| – | – | 0.03% | 126 |
|
|
2024
Q4 | $92.1K | Buy |
997
+139
| +16% | +$12.5K | 0.02% | 148 |
|
|
2024
Q3 | $71.9K | Hold |
858
| – | – | 0.02% | 166 |
|
|
2024
Q2 | $58.9K | Hold |
858
| – | – | 0.02% | 178 |
|
|
2024
Q1 | $62.8K | Hold |
858
| – | – | 0.02% | 165 |
|
|
2023
Q4 | $69.5K | Hold |
858
| – | – | 0.02% | 156 |
|
|
2023
Q3 | $64.3K | Buy |
858
+31
| +4% | +$2.38K | 0.02% | 161 |
|
|
2023
Q2 | $66.2K | Sell |
827
-213
| -20% | -$17K | 0.02% | 167 |
|
|
2023
Q1 | $85.5K | Buy |
1,040
+60
| +6% | +$4.97K | 0.03% | 182 |
|
|
2022
Q4 | $84.1K | Sell |
980
-500
| -34% | -$39.6K | 0.03% | 182 |
|
|
2022
Q3 | $91K | Sell |
1,480
-700
| -32% | -$44.1K | 0.03% | 172 |
|
|
2022
Q2 | $135K | Buy |
2,180
+727
| +50% | +$45K | 0.05% | 145 |
|
|
2022
Q1 | $86K | Buy |
1,453
+153
| +12% | +$9.78K | 0.03% | 203 |
|
|
2021
Q4 | $94K | Sell |
1,300
-200
| -13% | -$13.8K | 0.03% | 171 |
|
|
2021
Q3 | $105K | Buy |
+1,500
| New | +$105K | 0.04% | 149 |
|
|
2021
Q2 | – | Sell |
-1,600
| Closed | -$103K | – | 239 |
|
|
2021
Q1 | $103K | Buy |
+1,600
| New | +$103K | 0.04% | 153 |
|
|
2019
Q3 | – | Sell |
-60
| Closed | -$4K | – | 184 |
|
|
2019
Q2 | $4K | Hold |
60
| – | – | ﹤0.01% | 308 |
|
|
2019
Q1 | $4K | Hold |
60
| – | – | ﹤0.01% | 314 |
|
|
2018
Q4 | $4K | Hold |
60
| – | – | ﹤0.01% | 305 |
|
|
2018
Q3 | $5K | Hold |
60
| – | – | ﹤0.01% | 321 |
|
|
2018
Q2 | $4K | Hold |
60
| – | – | ﹤0.01% | 327 |
|
|
2018
Q1 | $5K | Sell |
60
-50
| -45% | -$3.98K | ﹤0.01% | 306 |
|
|
2017
Q4 | $9K | Hold |
110
| – | – | 0.01% | 271 |
|
|
2017
Q3 | $9K | Buy |
110
+50
| +83% | +$3.82K | 0.01% | 283 |
|
|
2017
Q2 | $4K | Hold |
60
| – | – | ﹤0.01% | 335 |
|
|
2017
Q1 | $4K | Sell |
60
-45
| -43% | -$3.16K | ﹤0.01% | 308 |
|
|
2016
Q4 | $8K | Buy |
+105
| New | +$7.8K | 0.01% | 276 |
|
Other funds holding GILD
Mascoma Wealth Management's GILD Position: Q2 2026 in Review
Mascoma Wealth Management increased its Gilead Sciences (GILD) stake by 0.59% in Q2 2026, buying an estimated $791 and bringing the position to 1,018 shares worth $129K. The position accounts for 0.02% of the portfolio, ranked #122.
Mascoma Wealth Management first reported a position in GILD in Q4 2016 and has held it in 32 quarters since. The position peaked at $141K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Mascoma Wealth Management held 1,018 shares of Gilead Sciences worth $129K as of Q2 2026.
- Mascoma Wealth Management bought 6 Gilead Sciences shares in Q2 2026, an estimated $791.
- Gilead Sciences made up 0.02% of Mascoma Wealth Management's portfolio in Q2 2026, its #122 holding.
- Mascoma Wealth Management first reported a position in Gilead Sciences in Q4 2016 and has held it in 32 quarters since.
- Mascoma Wealth Management's Gilead Sciences position peaked at $141K in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Mascoma Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.